恩度联合GP方案治疗晚期非小细胞肺癌的临床观察

Clinical observation of endostar combined GP regimen in advanced non-small cell lung cancer

目的探讨恩度联合吉西他滨、顺铂(GP)方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法回顾性分析40例经组织病理学证实的晚期(ⅢB/Ⅳ期)非小细胞肺癌患者的临床资料。40例初治患者均接受恩度联合GP方案的化疗。GP:吉西他滨1000mg/m2,第1、第8天,DDP 25mg/m2,第1～3天,每21天重复给药。同时给予恩度7.5mg/m2,每次用量15mg,静点4小时,第1～14天连续给药,间歇7天重复。2个周期后进行疗效评定,观察其疾病进展时间及不良反应。结果全部患者均接受2个周期以上化疗,共化疗142个周期。40例患者中CR为0例,PR为17例,SD为13例,PD为10例,客观有效率CR+PR(RR)为42.5%,疾病控制率为(CR+PR+SD)75.0%,中位疾病进展时间(mTTP)为11月。结论恩度联合GP方案治疗晚期非小细胞肺癌是一种安全、有效的治疗方法。不良反应轻,恢复快,患者耐受好。

Objective To observe the efficacy and safety of recombinant human endostatin injec- tion （endostar） combined with GP （gemcitabine plus cisplatin） regimen in patients with advanced non- small cell lung cancer （NSCLC）. Methods 40 cases of them were all treated by Gemcitabine and Cispla- tin（GP） regimen group. The patients were administered with endostar 15mg from day 1 to 14, gemcitabine 1 000mg/m2 day 1 and 8 ,cisplatin 25mg/m2 on days 1 to 3 ,repeated 21 days. Each patient should complete two cycles. Results 40 patients were valuable for response. NO patient achieved complete response （CR）, 17 partial response（PR） ,13 stable disease（SD） ,and 10 were found to have disease progression（PD）. The total response rate was 42. 5 %, median TTP was 11 months. Conclusions The response rate was 42. 5 %, clinical benefit rate was 75%, time to progression was 11 months. Endostar combined GP regimen was effec- tive and safe in treatment of advanced NSCLC.